Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Short Interest Update

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totaling 262,477 shares, a decline of 51.7% from the July 15th total of 542,999 shares. Based on an average daily trading volume, of 793,416 shares, the short-interest ratio is presently 0.3 days. Approximately 3.0% of the shares of the stock are short sold.

Institutional Investors Weigh In On Tvardi Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. acquired a new stake in shares of Tvardi Therapeutics during the second quarter valued at $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Tvardi Therapeutics in the second quarter valued at $43,000. Headlands Technologies LLC purchased a new stake in Tvardi Therapeutics during the second quarter valued at about $80,000. New York State Common Retirement Fund purchased a new stake in Tvardi Therapeutics during the second quarter valued at about $92,000. Finally, Squarepoint Ops LLC acquired a new stake in Tvardi Therapeutics during the third quarter worth about $318,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Stock Performance

NASDAQ:TVRD opened at $1.90 on Friday. Tvardi Therapeutics has a 1 year low of $1.50 and a 1 year high of $43.65. The stock has a fifty day moving average price of $2.49 and a two-hundred day moving average price of $3.19. The stock has a market capitalization of $17.82 million, a price-to-earnings ratio of -0.68 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, analysts predict that Tvardi Therapeutics will post -2.32 EPS for the current year.

Wall Street Analysts Forecast Growth

TVRD has been the topic of a number of recent research reports. BTIG Research lowered their price target on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 price target for the company in a report on Wednesday, July 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Wednesday, July 8th. Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a research note on Wednesday, July 8th. Finally, Wall Street Zen cut Tvardi Therapeutics to a “strong sell” rating in a research note on Saturday, July 18th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Tvardi Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $18.00.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.